Company Profile For GlaxoSmithkline Pharmaceutical Ltd

GlaxoSmithkline Pharmaceutical Ltd (GLAX.BO) (Bombay Stock Exchange)

sector: Healthcare · industry: Pharmaceuticals - Diversified ·

As of 3:40pm IST

1,633.90INR

Price Change

-0.80

Percent Change

-0.05%

Analyst Recommendations

Overview

GlaxoSmithKline Pharmaceuticals Limited is a pharmaceuticals company. The Company’s segments, in which its products are represented includes dermatologicals, corticosteroids, anti-infectives, vitamins, minerals, nutritionals and pain/analgesics. The Company’s products are used in various segments, including Augmentin in the anti-infectives segment; Betnesol, Eltroxin and Zentel in the corticosteroids, thyroid preparations and anti-parasitic segments; Calpol, Neosporin and Cobadex CZS in the anti-pyretic, topical antibiotic and antioxidants segments; Cetrizine in the oral solid segment, and Zobactin in the piperacillin combination segment. The Company’s flagship product in the field of Oncology is the Tykerb. The Company's wholly owned subsidiary is Biddle Sawyer Limited.

Quick Financial Synopsis

BRIEF: For the fiscal year ended 31 December 2008 GlaxoSmithKline Pharmaceuticals Limited's revenues increased 7% to RS18.15B. Net income before extraordinary items increased 14% to RS4.63B. Revenues reflect increased income from operation and higher other operating income. Net income also reflects improved operating margins and a decrease in depreciation expenses. The Company is engaged in the manufacturing of pharmaceutical products.